Doravirine
Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.
![]()  | |
| Clinical data | |
|---|---|
| Trade names | Pifeltro | 
| Other names | MK-1439 | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a618048 | 
| License data | 
  | 
| Routes of administration  | By mouth[1][2] | 
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.234.454 | 
| Chemical and physical data | |
| Formula | C17H11ClF3N5O3 | 
| Molar mass | 425.75 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
Doravirine was approved for medical use in the United States in August 2018.[5]
References
    
- "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
 - Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
 - "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 October 2020.
 - "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
 - "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.
 
External links
    
- "Doravirine". Drug Information Portal. U.S. National Library of Medicine.
 
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
